Qiagen NV

Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer.
Quotes
- Bid
- Ask
- Open
- Previous close
- Volume
- Relative volume
- High
- Low
Returns
Key stats
ESG risk
ESG risk is a measure of how well a company manages material ESG risks. Sustainalytics’ ESG risk category is designed to help investors identify and understand financially material ESG risks at the company level and how they might affect the long-term performance for equity investments. The scale is from 0-100. The lower the risk, the better (0 is equivalent to no risk and 100 the most severe).
Download ESG risk methodology (PDF)Financials
About Qiagen NV
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).
Others were interested in
See all stocksFrequently asked questions
To buy Qiagen NV stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Qiagen NV by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Qiagen NV is QGEN:xnys. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Qiagen NV has its primary listing on New York Stock Exchange. You can trade Qiagen NV with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Qiagen NV is available to trade on SaxoInvestor and SaxoTrader. You can buy shares directly and include Qiagen NV as part of a broader investment portfolio.